Previous 10 | Next 10 |
ImmuCell press release ( NASDAQ: ICCC ): Q2 GAAP EPS of -$0.09. Revenue of $3.86M (-15.0% Y/Y). For further details see: ImmuCell GAAP EPS of -$0.09, revenue of $3.86M
PORTLAND, Maine, Aug. 11, 2022 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the he...
PORTLAND, Maine, Aug. 04, 2022 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the he...
PORTLAND, Maine, July 27, 2022 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the he...
ImmuCell ( NASDAQ: ICCC ) announces preliminary sales results for Q2 of $3.9M, an decrease of 15% Y/Y. 1H sales of $9.9M, an increase of 14% Y/Y. “A material disruption in the supply to us of needed plastic parts limited our production and sales during the qua...
PORTLAND, Maine, July 07, 2022 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the he...
ImmuCell Corporation (ICCC) Q1 2022 Earnings Conference Call May 13, 2022 09:00 AM ET Company Participants Joe Diaz - Lytham Partners, IR Michael Brigham - President and CEO Joseph Crabb - Former Chief Scientific Officer and VP Presentation Operator Good morning. This is Andrea from Chorus Ca...
PORTLAND, Maine, May 12, 2022 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the hea...
PORTLAND, Maine, May 10, 2022 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the hea...
PORTLAND, Maine, May 05, 2022 (GLOBE NEWSWIRE) -- Certain immaterial corrections have been made to the second and fifth paragraphs. ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manu...
News, Short Squeeze, Breakout and More Instantly...
PORTLAND, Maine , June 05, 2024 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the he...
PORTLAND, Maine, May 14, 2024 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health an...
AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...